Shares in Issue

The current number of ordinary shares in issue as of 13th February 2024 is 361,775,664. 11% of Psych Capital’s ordinary shares are held in public hands.

Options / Warrants

At Admission share options will have been granted under a share option scheme over 31,835,832 Ordinary Shares to the Directors, Proposed Director, Technical Advisory Board, Founders and employees of the Company, representing 10.98 per cent. of the Issued Share Capital immediately following Admission.

The Company has granted 10,000,000 share options over ordinary shares of the Company, as part of a new unapproved share option scheme, to existing directors. Details of the Share Options can be found in the announcement dated 25 February 2024.

Warrant Holder: Peterhouse Capital Ltd
Total No. of Warrants: 14,501,667
Exercise Price: £0.05
Period: Up to the 5th anniversary of Admission

Restrictions on Share Transfer

Ordinary Shares are freely transferrable

Significant Shareholders

Percentage of issued share capital on Admission
Prohibition Holdings Limited – 90,000,000
Christopher Potts – 54,787,297
Oscillate plc – 46,840,384
Peterhouse Capital Limited –16,038,843
William Potts – 10,731,233
Robert Reid – 10,528,210
Rivki Stern – 9,394,231
Roy Kait – 7,308,830

The Directors are committed to maintaining high standards of corporate governance, and, so far as is practicable given the Company’s size and nature, to comply with the QCA Code.

The Board holds at least six board meetings a year and will also hold timely board meetings as and when issues arise which require its attention. The Board is responsible for the management of the business of the Company, setting the strategic direction of the Company.

The Board has 4 formally established committees – Remuneration, Audit, AQSE Rules Compliance and an Executive Committee. The Board has also established a Psychedelic Medicines Technical Advisory Board consisting of industry experts.

The Company has established Financial Position and Prospects procedures and adopted an anti-bribery and corruption policy.

Investor Information

17 Hanover Square,
London W1S 1BN
United Kingdom

Tel: +442038387621
Email: i[email protected]